Form D · Other
ZBiotics Co
San Francisco, CA · CIK 0001807168
Offering snapshot reported Apr 9, 2024 · SEC filing
- Reported sold
- $22.4M Offering amount: $22.4M
- Investors reported
- 68 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 9, 2024 | Initial | $22,423,339 | No comparison | 68 | SEC filing |
| Mar 24, 2020 | Initial | $5,691,137 | No comparison | 38 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-510055
Includes $8,423,351.35 in value of cancelled convertible securities, and includes $1,999,999.92 in value of equity securities issued in exchange for existing capital stock of the Issuer.
Source: Form D, filed Apr 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Zachary Donald Abbott | Director, Executive |
| Stephen Lamb | Director, Executive |
| Adam Ramada | Director |
Issuer details
Industry: Other (See others in industry)
Address:
44 Montgomery Street Suite 300
San Francisco, CA, 94104
San Francisco, CA, 94104